Drug combo vs. targeted radiation: Head-to-Head liver cancer trial halted early

This study aimed to find out which initial treatment works better for people with a specific stage of liver cancer that is too large for surgery but hasn't spread. It directly compared a two-drug immunotherapy combination (atezolizumab and bevacizumab) against localized treatments that deliver chemotherapy or radiation beads directly to the liver (TACE or TARE). The main goal was to see which approach kept the cancer from growing for the longest time. The trial was terminated early after enrolling only one participant.